Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GVGH 1790GAHB Vaccine in Kenyan Adults
NCT02676895Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2016
- Primary completion
- Mar 2017
- Modality
- Lipid-based Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GVGH Shigella sonnei 1790GAHB vaccine in shigellosis, sponsored by GSK. Started Aug 2016; status: completed.
02
Drugs
GVGH Shigella sonnei 1790GAHB vaccine
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT02676895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676895.